<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Neuropsychopharmacology</journal-id>
<journal-id journal-id-type="iso-abbrev">Neuropsychopharmacology</journal-id>
<journal-title-group>
<journal-title>Neuropsychopharmacology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0893-133X</issn>
<issn pub-type="epub">1740-634X</issn>
<publisher>
<publisher-name>Nature Publishing Group</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26708105</article-id>
<article-id pub-id-type="pmc">4908636</article-id>
<article-id pub-id-type="pii">npp2015369</article-id>
<article-id pub-id-type="doi">10.1038/npp.2015.369</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Targeting Translation Control with p70 S6 Kinase 1 Inhibitors to Reverse Phenotypes in Fragile X Syndrome Mice</article-title>
<alt-title alt-title-type="running">S6K1 inhibitors reverse phenotypes in FXS mice</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Bhattacharya</surname>
<given-names>Aditi</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="author-notes" rid="note1">
<sup>6</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mamcarz</surname>
<given-names>Maggie</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mullins</surname>
<given-names>Caitlin</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Choudhury</surname>
<given-names>Ayesha</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Boyle</surname>
<given-names>Robert G</given-names>
</name>
<xref ref-type="aff" rid="aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Smith</surname>
<given-names>Daniel G</given-names>
</name>
<xref ref-type="aff" rid="aff5">5</xref>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4637-8992</contrib-id>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Walker</surname>
<given-names>David W</given-names>
</name>
<xref ref-type="aff" rid="aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Klann</surname>
<given-names>Eric</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="corresp" rid="caf1">*</xref>
</contrib>
<aff id="aff1"><label>1</label><institution>Center for Neural Science, New York University</institution>, New York, NY, <country>USA</country></aff>
<aff id="aff2"><label>2</label><institution>New York University Neuroscience Institute, New York University Langone Medical Center</institution>, New York, NY, <country>USA</country></aff>
<aff id="aff3"><label>3</label><institution>Department of Psychology, Hunter College, City University of New York</institution>, New York, NY, <country>USA</country></aff>
<aff id="aff4"><label>4</label><institution>Sentinel Oncology</institution>, Cambridge, <country>UK</country></aff>
<aff id="aff5"><label>5</label><institution>Autism Speaks</institution>, Boston, MA, <country>USA</country></aff>
</contrib-group>
<author-notes>
<corresp id="caf1"><label>*</label><institution>Center for Neural Science, New York University</institution>, 4 Washington Place, Room 809, New York, NY 10003, <country>USA</country>, Tel: +1 212 992 9769, E-mail: <email>eklann@cns.nyu.edu</email></corresp>
<fn fn-type="present-address" id="note1">
<label>6</label>
<p>Current address: Center for Brain Development and Repair, Institute for Stem Cell Biology and Regenerative Medicine, National Center for Biological Sciences, GKVK Campus, Bangalore 560065, India</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<month>07</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epreprint">
<day>28</day>
<month>12</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="epub">
<day>20</day>
<month>01</month>
<year>2016</year>
</pub-date>
<volume>41</volume>
<issue>8</issue>
<fpage>1991</fpage>
<lpage>2000</lpage>
<history>
<date date-type="received">
<day>12</day>
<month>10</month>
<year>2015</year>
</date>
<date date-type="rev-recd">
<day>11</day>
<month>12</month>
<year>2015</year>
</date>
<date date-type="accepted">
<day>22</day>
<month>12</month>
<year>2015</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright Â© 2016 American College of Neuropsychopharmacology</copyright-statement>
<copyright-year>2016</copyright-year>
<copyright-holder>American College of Neuropsychopharmacology</copyright-holder>
</permissions>
<abstract>
<p>Aberrant neuronal translation is implicated in the etiology of numerous brain disorders. Although mTORC1-p70 ribosomal S6 kinase 1 (S6K1) signaling is critical for translational control, pharmacological manipulation <italic>in vivo</italic> has targeted exclusively mTORC1 due to the paucity of specific inhibitors to S6K1. However, small molecule inhibitors of S6K1 could potentially ameliorate pathological phenotypes of diseases, which are based on aberrant translation and protein expression. One such condition is fragile X syndrome (FXS), which is considered to be caused by exaggerated neuronal translation and is the most frequent heritable cause of autism spectrum disorder (ASD). To date, potential therapeutic interventions in FXS have focused largely on targets upstream of translational control to normalize FXS-related phenotypes. Here we test the ability of two S6K1 inhibitors, PF-4708671 and FS-115, to normalize translational homeostasis and other phenotypes exhibited by FXS model mice. We found that although the pharmacokinetic profiles of the two S6K1 inhibitors differed, they overlapped in reversing multiple disease-associated phenotypes in FXS model mice including exaggerated protein synthesis, inappropriate social behavior, behavioral inflexibility, altered dendritic spine morphology, and macroorchidism. In contrast, the two inhibitors differed in their ability to rescue stereotypic marble-burying behavior and weight gain. These findings provide an initial pharmacological characterization of the impact of S6K1 inhibitors <italic>in vivo</italic> for FXS, and have therapeutic implications for other neuropsychiatric conditions involving aberrant mTORC1-S6K1 signaling.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>